尿毒清颗粒联合非布司他治疗高尿酸血症肾损害患者研究

doi:10.3969/j.issn.1006-5725.2024.10.015

Abstract

Abstract:

Objective To investigate the clinical efficacy of Niaoduqing Granule combined with Febusta in the treatment of renal damage in patients with hyperuricemia （HUA）. Methods Eighty-two HUA patients with renal damage in our hospital from March 2020 to March 2022 were divided into observation group （n = 41） and control group （n = 41）. The control group was treated with Febusta， while observation group with Niaoduqing granule and Febusta. Two groups were treated for 12 weeks. Blood uric acid， renal function， Cys C and β2-MG level change and adverse reactions in the two groups were compared. Results The total effective rate in the observation group was higher than in the control group （P < 0.05）. After treatment， the level of serum uric acid， BUN， Scr， 24h Upro， Cys C and β2-MG decreased in the two groups （P < 0.05）， with more significant results in the observation group （P < 0.05）. No obvious adverse reactions were observed in the two groups. Conclusion Niaoduqing Granule combined with Febusta has good effect in treating HUA patients with renal impairment. It reduces the level of blood uric acid， Cys C and β2-MG， which protect the renal function of patients，

Key words: Niaoduqing Granule, Febusta tablet, hyperuricemia, renal damage

CLC Number:

R977

Juan LI,Lin. YANG. Clinical efficacy of Niaoduqing Granule combined with Febusta in treatment of hyperuricemia with renal damage[J]. The Journal of Practical Medicine, 2024, 40(10): 1418-1422.

Figures/Tables 5

Fig.1

Tab.1

Tab.2

Tab.3

Tab.4

References 23

1	YANAI H， ADACHI H， HAKOSHIMA M， et al. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome， Cardiovascular Diseases and Chronic Kidney Disease［J］. Int J Mol Sci， 2021， 22（17）：9221. doi:10.3390/ijms22179221 doi: 10.3390/ijms22179221
2	ZHANG M， CUI R， ZHOU Y， et al. Accumulation of Renal Fibrosis in Hyperuricemia Rats Is Attributed to the Recruitment of Mast Cells， Activation of the TGF-β1/Smad2/3 Pathway， and Aggravation of Oxidative Stress［J］. Int J Mol Sci， 2023， 24（13）：10839. doi:10.3390/ijms241310839 doi: 10.3390/ijms241310839
3	WANG J， CHEN Y， ZHONG H， et al. The gut microbiota as a target to control hyperuricemia pathogenesis： Potential mechanisms and therapeutic strategies［J］. Crit Rev Food Sci Nutr， 2022，62（14）：3979-3989. doi:10.1080/10408398.2021.1874287 doi: 10.1080/10408398.2021.1874287
4	SU H Y， YANG C， LIANG D， et al. Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury［J］. Biomed Res Int， 2020， 2020：5817348. doi:10.1155/2020/5817348 doi: 10.1155/2020/5817348
5	LI H， LIU X， LEE M H， et al. Vitamin C alleviates hyperuricemia nephropathy by reducing inflammation and fibrosis［J］. J Food Sci， 2021， 86（7）：3265-3276. doi:10.1111/1750-3841.15803 doi: 10.1111/1750-3841.15803
6	YANG H T， XIU W J， LIU J K， et al. Gut Microbiota Characterization in Patients with Asymptomatic Hyperuricemia： probiotics increased［J］. Bioengineered，2021，12（1）：7263-7275. doi:10.1080/21655979.2021.1976897 doi: 10.1080/21655979.2021.1976897
7	LI F， WANG M， WANG J， et al. Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease［J］. Front Cell Infect Microbiol， 2019，9：206. doi:10.3389/fcimb.2019.00206 doi: 10.3389/fcimb.2019.00206
8	CRISTOBAL-GARCIA M， GARCIA-ARROYO F E， TAPIA E， et al. Renal oxi dative stress induced by long-term hyperuricemia alters mitochon drial function and maintains systemic hypertension［J］. Oxid Med Cell Longev， 2015，2015：535686. doi:10.1155/2015/535686 doi: 10.1155/2015/535686
9	高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识［J］. 中华内科杂志， 2017，56（3）：235-248. doi:10.3760/cma.j.issn.0578-1426.2017.03.021 doi: 10.3760/cma.j.issn.0578-1426.2017.03.021
10	PAN J， SHI M， MA L， et al. Mechanistic insights of soluble uric acid-related kidney disease［J］. Curr Med Chem， 2020， 27（30）： 5056-5066. doi:10.2174/0929867326666181211094421 doi: 10.2174/0929867326666181211094421
11	XIONG C， DENG J， WANG X， et al. Pharmacologic targeting of BET proteins attenuates hyperuricemic nephropathy in rats［J］. Front Pharm， 2021， 12： 636154. doi:10.3389/fphar.2021.636154 doi: 10.3389/fphar.2021.636154
12	ZENNARO C， TONON F， ZARATTINI P， et al. The renal phenotype of allopurinol-treated HPRT-deficient mouse［J］. PLoS One， 2017， 12（3）： e0173512. doi:10.1371/journal.pone.0173512 doi: 10.1371/journal.pone.0173512
13	ZHANG D， HUANG Q F， LI Y， et al. Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination［J］. Blood Press Monit， 2021，26（6）：413-418. doi:10.1097/mbp.0000000000000554 doi: 10.1097/mbp.0000000000000554
14	SUN Z R， LIU H R， HU D， et al. Ellagic Acid Exerts Beneficial Effects on Hyperuricemia by Inhibiting Xanthine Oxidase and NLRP3 Inflammasome Activation［J］. J Agric Food Chem， 2021，69（43）：12741-12752. doi:10.1021/acs.jafc.1c05239 doi: 10.1021/acs.jafc.1c05239
15	CHEN F， YUAN L， XU T， et al. Association of Hyperuricemia with 10-Year Atherosclerotic Cardiovascular Disease Risk among Chinese Adults and Elders［J］. Int J Environ Res Public Health， 2022， 19： 6713. doi:10.3390/ijerph19116713 doi: 10.3390/ijerph19116713
16	LONG T， LIU L. Research Progress on the Relationship between Dietary Patterns and Hyperuricemia ［J］. Appl Bionics Biomech， 2022， 2022： 1263-1270. doi:10.1155/2022/5658423 doi: 10.1155/2022/5658423
18	伍成凯，廖生武，方浩庭，等. 广州市成年人高尿酸血症患病情况调查及其影响因素分析［J］. 实用医学杂志， 2021， 37（23）： 3072-3076. doi:10.3969/j.issn.1006-5725.2021.23.022 doi: 10.3969/j.issn.1006-5725.2021.23.022
19	LIU P， MA G， WANG Y， et al. Therapeutic effects of traditional Chinese medicine on gouty nephropathy： Based on NF-κB signaling pathways［J］. Biomed Pharmacother， 2023， 158：114199. doi:10.1016/j.biopha.2022.114199 doi: 10.1016/j.biopha.2022.114199
20	MIRONOVA O I. Hyperuricemia and kidney damage in patients with cardiovascular disease： A review［J］. Ter Arkh， 2023， 4（12）：1426-1430. doi:10.26442/00403660.2022.12.201999 doi: 10.26442/00403660.2022.12.201999
21	陈如萍，刘蕊，孙遨，等. 基于社区老年健康体检人群的慢性肾脏病流行病学调查［J］. 实用医学杂志， 2021， 37（13）： 1755-1760.
22	YU C S H， FANG H H， YU Z P， et al. Overview of advances in Chinese medicine for the treatment of gouty nephropathy［J］， J Emerg Tradit Chin Med， 2020， 29： 4.
23	郭文燕，李燕林. 尿毒康合剂联合非布司他治疗湿热瘀阻型痛风性肾病疗效评价［J］. 广州中医药大学学报， 2021，38（7）：1335-1340.

组别	例数	临床控制	显效	有效	无效	总有效
观察组	41	6（14.63）	20（48.78）	10（24.39）	5（12.20）	36（87.80）
对照组	41	2（4.88）	14（34.15）	12（29.27）	13（31.71）	28（68.29）
χ ² 值						4.556
P值						0.033

组别	例数	治疗前	治疗后
观察组	41	473.24 ± 42.31	367.52 ± 27.41^*
对照组	41	469.82 ± 48.45	408.91 ± 30.53^*
t值		0.340	6.459
P值		0.734	< 0.001

组别	例数	BUN（mmol/L）		Scr（μmol/L）		24h Upro（g）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	41	6.31 ± 0.61	5.24 ± 0.34^*	87.84 ± 4.31	72.31 ± 5.64^*	1.89 ± 0.25	1.25 ± 0.17^*
对照组	41	6.28 ± 0.56	5.78 ± 0.42^*	88.53 ± 5.08	81.29 ± 6.07^*	1.92 ± 0.31	1.56 ± 0.22^*
t值		0.232	6.399	0.663	6.940	0.482	7.139
P值		0.817	< 0.001	0.509	< 0.001	0.631	< 0.001

组别	例数	Cys C（mg/L）		β2-MG（mg/L）
组别	例数	治疗前	治疗后	治疗前	治疗后
观察组	41	1.32 ± 0.27	0.70 ± 0.15^*	0.24 ± 0.05	0.13 ± 0.04^*
对照组	41	1.30 ± 0.34	0.96 ± 0.18^*	0.23 ± 0.08	0.18 ± 0.05^*
t值		0.295	7.105	0.679	5.000
P值		0.769	< 0.001	0.499	< 0.001

[1]	Jianlong SHENG,Ni′na. LIU. The advanced progress on the relationship between hyperuricemia and acute myocardial infarction [J]. The Journal of Practical Medicine, 2024, 40(5): 727-730.
[2]	Yuan YANG,Peng HU,Yan. HUANG. Current status of knowledge， attitude and practice of hyperuricemia health management in community medical staff based on mixed methods study [J]. The Journal of Practical Medicine, 2024, 40(14): 2015-2020.
[3]	WANG Xianfang, LIU Zhidong, ZHANG Yuan, HUANG Changjing, ZHANG Haifei, YU Liqiong, ZHONG Wei.. Association of ABCG2 rs 2231142 and SLC2A9rs 3733591 gene polymorphisms with hyperuricemia in Southern Han population [J]. The Journal of Practical Medicine, 2023, 39(7): 875-880.
[4]	SONG Caixia, YAN Ting, YAN Zhenyuan, YU Yulan.. Clinical observation on the improvement of residual renal function in hemodialysis patients with bp⁃nacombined with Niaoduqing [J]. The Journal of Practical Medicine, 2022, 38(4): 494-497.
[5]	PANG Chengzhang, LIU Wenbin, JIN Xiaobao. “Relocalization”of anti⁃hyperuricemia drugs based on disease gene expression Profile and Drug transcrip⁃ tome [J]. The Journal of Practical Medicine, 2022, 38(22): 2838-2844.
[6]	YUAN Bingkun, LIAO Shengwu, WU Chengkai, PENG Cheng, CHEN Lei, LI Wenyuan.. Study on the relationship between daily sleep duration and the prevalence of hyperuricemia among urban workers in Guangzhou [J]. The Journal of Practical Medicine, 2022, 38(15): 1948-1953.
[7]	WU Chengkai, LIAO Shengwu, FANG Haoting, WANG Yuanyuan, LI Wenyuan. . Analysis of prevalence and risk factors of hyperuricemia among adults in Guangzhou [J]. The Journal of Practical Medicine, 2021, 37(23): 3072-3076.
[8]	LI Luwei, HUANG Qian, SHI Jiacheng, LIU Xiaoling, WANG Caimei, YU Ping, WU Lan, QIN Yang, JIANG Ren⁃ mei, YU Jian.. Construction and evaluation of hyperuricemia prediction model for overweight and obese population [J]. The Journal of Practical Medicine, 2021, 37(18): 2401-2406.

Clinical efficacy of Niaoduqing Granule combined with Febusta in treatment of hyperuricemia with renal damage

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 23

Related Articles 8

Recommended Articles

Metrics

Comments